1
|
Sildenafil Citrate Enhances Renal Organogenesis Following Metanephroi Allotransplantation into Non-Immunosuppressed Hosts. J Clin Med 2022; 11:jcm11113068. [PMID: 35683456 PMCID: PMC9181797 DOI: 10.3390/jcm11113068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Revised: 05/14/2022] [Accepted: 05/27/2022] [Indexed: 12/27/2022] Open
Abstract
In order to harness the potential of metanephroi allotransplantation to the generation of a functional kidney graft on demand, we must achieve further growth post-transplantation. Sildenafil citrate (SC) is widely known as a useful inductor of angiogenesis, offering renoprotective properties due to its anti-inflammatory, antifibrotic, and antiapoptotic effects. Here, we performed a laparoscopic metanephroi allotransplantation after embedding sildenafil citrate into the retroperitoneal fat of non-immunosuppressed adult rabbit hosts. Histology and histomorphometry were used to examine the morphofunctional changes in new kidneys 21 days post-transplantation. Immunofluorescence of E-cadherin and renin and erythropoietin gene expression were used to assess the tubule integrity and endocrine functionality. After the metanephroi were embedded in a 10 µM SC solution, the new kidneys’ weights become increased significantly. The E-cadherin expression together with the renin and erythropoietin gene expression revealed its functionality, while histological mature glomeruli and hydronephrosis proved the new kidneys’ excretory function. Thus, we have described a procedure through the use of SC that improves the outcomes after a metanephroi transplantation. This study gives hope to a pathway that could offer a handsome opportunity to overcome the kidney shortage.
Collapse
|
2
|
Ding B, Sun G, Liu S, Peng E, Wan M, Chen L, Jackson J, Atala A. Three-Dimensional Renal Organoids from Whole Kidney Cells: Generation, Optimization, and Potential Application in Nephrotoxicology In Vitro. Cell Transplant 2021; 29:963689719897066. [PMID: 32166969 PMCID: PMC7504083 DOI: 10.1177/0963689719897066] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The kidney function of patients with chronic kidney disease (CKD) is impaired
irreversibly. Organ transplantation is the only treatment to restore kidney function in
CKD patients. The assessment of new potential therapeutic procedures relies heavily on
experimental animal models, but it is limited by its human predictive capacity. In
addition, the frequently used two-dimensional in vitro human renal cell
models cannot replicate all the features of the in vivo situation. In this study, we
developed a three-dimensional (3D) in vitro human renal organoid model
from whole kidney cells as a promising drug screening tool. At present, the renal tissue
generated from human pluripotent stem cells (hPSCs) exhibits intrinsic tumorigenicity
properties. Here we first developed a 3D renal organoid culture system that originated
from adult differentiated cells without gene modification. Renal organoids composed of
multiple cell types were created under optimal experimental conditions and evaluated for
morphology, viability and erythropoietin production. As a novel screening tool for renal
toxicity, 3D organoids were exposed to three widely used drugs: aspirin, penicillin G and
cisplatin. The study results showed this 3D renal organoid model can be used as a drug
screening tool, a new in vitro 3D human kidney model, and provide hope
for potential regenerative therapies for CKD.
Collapse
Affiliation(s)
- Beichen Ding
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HB, China.,Department of Urinary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, HLJ, China
| | - Guoliang Sun
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HB, China
| | - Shiliang Liu
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HB, China
| | - Ejun Peng
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HB, China
| | - Meimei Wan
- Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA
| | - Liang Chen
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, HB, China.,Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA
| | - John Jackson
- Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA
| | - Anthony Atala
- Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA
| |
Collapse
|
3
|
Abstract
Biofabrication of tissue analogues is aspiring to become a disruptive technology capable to solve standing biomedical problems, from generation of improved tissue models for drug testing to alleviation of the shortage of organs for transplantation. Arguably, the most powerful tool of this revolution is bioprinting, understood as the assembling of cells with biomaterials in three‐dimensional structures. It is less appreciated, however, that bioprinting is not a uniform methodology, but comprises a variety of approaches. These can be broadly classified in two categories, based on the use or not of supporting biomaterials (known as “scaffolds,” usually printable hydrogels also called “bioinks”). Importantly, several limitations of scaffold‐dependent bioprinting can be avoided by the “scaffold‐free” methods. In this overview, we comparatively present these approaches and highlight the rapidly evolving scaffold‐free bioprinting, as applied to cardiovascular tissue engineering.
Collapse
Affiliation(s)
- Nicanor I Moldovan
- Departments of Biomedical Engineering and Ophthalmology, 3D Bioprinting Core, Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA
| |
Collapse
|
4
|
Moldovan L, Babbey CM, Murphy MP, Moldovan NI. Comparison of biomaterial-dependent and -independent bioprinting methods for cardiovascular medicine. CURRENT OPINION IN BIOMEDICAL ENGINEERING 2017. [DOI: 10.1016/j.cobme.2017.05.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|